ABVC BioPharma Reports $2.5 Million Net Loss for Six Months Ending June 30, 2026

ABVC BioPharma, Inc. reported a net loss of $2.5 million for the six months ending June 30, 2026, a decrease from a loss of $3.3 million during the same period in 2025. The company did not generate any revenue during this period, consistent with the previous year. Operating expenses totaled approximately $2.35 million, down from $2.99 million in the prior year, primarily due to reduced selling, general, and administrative expenses, which fell from $1.31 million to $1.26 million. The company’s cash and cash equivalents decreased significantly to $31,944 from $681,480 at the end of the previous fiscal year, reflecting ongoing financial challenges.

In terms of operational changes, ABVC BioPharma has undergone a strategic reorganization, including the planned partial legal and structural separation of its subsidiary, BioKey Cayman. This separation is intended to enhance shareholder value and is expected to result in the distribution of approximately 4.5 million shares of BioKey Cayman to ABVC shareholders. The distribution was initially scheduled for August 3, 2026, but has been postponed due to regulatory matters. The company also continues to focus on its collaborative agreements, including licensing deals with ForSeeCon Eye Corporation and OncoX BioPharma, which could yield future revenue through milestone payments and royalties.

The company’s total assets decreased to $19.4 million as of June 30, 2026, down from $21.1 million at the end of 2025. This decline was primarily driven by a reduction in cash and cash equivalents and restricted cash, which fell from $681,480 to $31,944. Total liabilities also decreased to $7.13 million from $7.76 million, with current liabilities accounting for the majority of this figure. The company’s working capital deficit stood at $5.28 million, raising concerns about its ability to continue as a going concern without additional financing or operational improvements.

ABVC BioPharma's employee headcount has remained stable, with no significant changes reported in staffing levels. The company continues to engage in research and development activities, focusing on its pipeline of drug candidates derived from plant sources. However, the lack of revenue generation and the ongoing financial losses highlight the need for the company to secure additional funding or partnerships to sustain its operations and support future growth.

Looking ahead, ABVC BioPharma's management has indicated plans to improve operations and generate positive cash flows. The company is exploring various financing options, including private and public capital raising activities, to bolster its financial position. However, the uncertainty surrounding its ability to generate revenue and the substantial doubt regarding its ability to continue as a going concern remain significant challenges for the company in the near term.